Antoine Hollebecque

Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations

David M. Hyman, Igor Puzanov, Vivek Subbiah et al. · New England Journal of Medicine · 2015 · 1.7K citations · Full text

Medicine, Oncology, Pharmacology +12

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study

Ghassan K. Abou‐Alfa, Vaibhav Sahai, Antoine Hollebecque et al. · The Lancet Oncology · 2020 · 1.6K citations · Full text

Medicine, Oncology, Pharmacology +11

Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Michel Ducreux, Caroline Caramella, Antoine Hollebecque et al. · Annals of Oncology · 2015 · 1.3K citations · Full text

Medicine, Oncology, Surgery +12

A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study

Roger Sun, Elaine Johanna Limkin, Maria Vakalopoulou et al. · The Lancet Oncology · 2018 · 1.2K citations

Medicine, Immunology, Oncology +17

Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1

Stéphane Champiat, Laurent Dercle, Samy Ammari et al. · Clinical Cancer Research · 2016 · 1.2K citations

Medicine, Oncology, Pharmacology +17